Asset sale Pending
TransCode Therapeutics acquisition of Unleash-owned rights to UIO-524, UIO-525 and UIO-526
Announced 3 Mar 2026
Advisers
Unleash-owned rights to UIO-524, UIO-525 and UIO-526
Target
Not disclosed
TransCode Therapeutics
Acquirer
Not disclosed
Other advisers
- Financial adviser
- Target
- Unleash-owned rights to UIO-524, UIO-525 and UIO-526
- Acquirer
- TransCode Therapeutics
- Seller
- Unleash Immuno Oncolytics
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Passage Bio and Remix Therapeutics merger Jun 2026 · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Rallybio acquisition of Avenzo Therapeutics Jun 2026 · Biotech